Please use this identifier to cite or link to this item:
|Title:||IMWG consensus on risk stratification in multiple myeloma||Authors:||Chng, W.J.
|Issue Date:||Feb-2014||Citation:||Chng, W.J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N., Palumbo, A., Miguel, J.S., Sonneveld, P., Cavo, M., Usmani, S., Durie, B.G., Avet-Loiseau, H. (2014-02). IMWG consensus on risk stratification in multiple myeloma. Leukemia 28 (2) : 269-277. ScholarBank@NUS Repository. https://doi.org/10.1038/leu.2013.247||Abstract:||Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies. © 2014 Macmillan Publishers Limited.||Source Title:||Leukemia||URI:||http://scholarbank.nus.edu.sg/handle/10635/126925||ISSN:||08876924||DOI:||10.1038/leu.2013.247|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Aug 1, 2021
WEB OF SCIENCETM
checked on Jul 11, 2019
checked on Jul 31, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.